Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005838 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
NCT00005838: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00005838 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 756 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005838, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. AE-941 may help shrink or slow the growth of non-small cell lung cancer cells. It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without AE-941 for non-small cell lung cancer. This randomized phase III trial is studying combination chemotherapy and radiation therapy given with AE-941 to see how well they work compared to combination chemotherapy and radiation therapy alone in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery
Interventions
- OTHER placebo
- DRUG cisplatin
- DRUG carboplatin
- DRUG vinorelbine tartrate
- DRUG shark cartilage extract AE-941
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2000-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005838
The ClinicalTrials.gov registry entry for NCT00005838 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00005838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005838 about?
NCT00005838 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. AE-941 may help shrink or slow the growth of non-small cell lung cance...
What is the current status of trial NCT00005838?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2000-03.
What interventions are being tested in trial NCT00005838?
The interventions under investigation include: placebo (OTHER), cisplatin (DRUG), carboplatin (DRUG), vinorelbine tartrate (DRUG), shark cartilage extract AE-941 (DRUG).
Who is sponsoring clinical trial NCT00005838?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.